Drugs for Non-Small Cell Lung Cancer Market - Global Outlook and Forecast 2021-2027
Report Code: KNJ1034076 No. of Pages: 113 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of Drugs for Non-Small Cell Lung Cancer in Global, including the following market information:
Global Drugs for Non-Small Cell Lung Cancer Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Drugs for Non-Small Cell Lung Cancer market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Non-Small Cell Lung Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Non-Small Cell Lung Cancer Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Drugs for Non-Small Cell Lung Cancer Market Segment Percentages, By Type, 2020 (%)
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
China Drugs for Non-Small Cell Lung Cancer Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Drugs for Non-Small Cell Lung Cancer Market Segment Percentages, By Application, 2020 (%)
Hospitals
Clinics
Other
Global Drugs for Non-Small Cell Lung Cancer Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Drugs for Non-Small Cell Lung Cancer Market Segment Percentages, By Region and Country, 2020 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Total Drugs for Non-Small Cell Lung Cancer Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Drugs for Non-Small Cell Lung Cancer Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
1 Introduction to Research & Analysis Reports
1.1 Drugs for Non-Small Cell Lung Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Non-Small Cell Lung Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Non-Small Cell Lung Cancer Overall Market Size
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size: 2021 VS 2027
2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Non-Small Cell Lung Cancer Players in Global Market
3.2 Top Global Drugs for Non-Small Cell Lung Cancer Companies Ranked by Revenue
3.3 Global Drugs for Non-Small Cell Lung Cancer Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Non-Small Cell Lung Cancer Companies in Global Market, by Revenue in 2020
3.5 Global Companies Drugs for Non-Small Cell Lung Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Non-Small Cell Lung Cancer Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Non-Small Cell Lung Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Non-Small Cell Lung Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Non-Small Cell Lung Cancer Market Size Markets, 2021 & 2027
4.1.2 Radiofrequency Ablation (RFA)
4.1.3 Radiation Therapy
4.1.4 Chemotherapy
4.1.5 Targeted Therapies
4.1.6 Immunotherapy
4.2 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue & Forecasts
4.2.1 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2021
4.2.2 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2022-2027
4.2.3 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Non-Small Cell Lung Cancer Market Size, 2021 & 2027
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue & Forecasts
5.2.1 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2021
5.2.2 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2022-2027
5.2.3 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Drugs for Non-Small Cell Lung Cancer Market Size, 2021 & 2027
6.2 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue & Forecasts
6.2.1 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2021
6.2.2 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2022-2027
6.2.3 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2027
6.3.2 US Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.3.3 Canada Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.3.4 Mexico Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2027
6.4.2 Germany Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4.3 France Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4.4 U.K. Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4.5 Italy Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4.6 Russia Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4.7 Nordic Countries Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.4.8 Benelux Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2027
6.5.2 China Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.5.3 Japan Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.5.4 South Korea Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.5.5 Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.5.6 India Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2027
6.6.2 Brazil Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.6.3 Argentina Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue, 2016-2027
6.7.2 Turkey Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.7.3 Israel Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.7.4 Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
6.7.5 UAE Drugs for Non-Small Cell Lung Cancer Market Size, 2016-2027
7 Players Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Corporate Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.1.4 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.1.5 Bristol-Myers Squibb Key News
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporate Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.2.4 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.2.5 GlaxoSmithKline Key News
7.3 Menarini
7.3.1 Menarini Corporate Summary
7.3.2 Menarini Business Overview
7.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.3.4 Menarini Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.3.5 Menarini Key News
7.4 Sanofi
7.4.1 Sanofi Corporate Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.4.4 Sanofi Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.4.5 Sanofi Key News
7.5 Ziopharm Oncology
7.5.1 Ziopharm Oncology Corporate Summary
7.5.2 Ziopharm Oncology Business Overview
7.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.5.4 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.5.5 Ziopharm Oncology Key News
7.6 Alchemia
7.6.1 Alchemia Corporate Summary
7.6.2 Alchemia Business Overview
7.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.6.4 Alchemia Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.6.5 Alchemia Key News
7.7 Amgen
7.7.1 Amgen Corporate Summary
7.7.2 Amgen Business Overview
7.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.4.4 Amgen Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.7.5 Amgen Key News
7.8 Apotex
7.8.1 Apotex Corporate Summary
7.8.2 Apotex Business Overview
7.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.8.4 Apotex Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.8.5 Apotex Key News
7.9 BioMarin Pharmaceutical
7.9.1 BioMarin Pharmaceutical Corporate Summary
7.9.2 BioMarin Pharmaceutical Business Overview
7.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.9.4 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.9.5 BioMarin Pharmaceutical Key News
7.10 CellAct Pharma
7.10.1 CellAct Pharma Corporate Summary
7.10.2 CellAct Pharma Business Overview
7.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.10.4 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.10.5 CellAct Pharma Key News
7.11 Cerulean Pharma
7.11.1 Cerulean Pharma Corporate Summary
7.11.2 Cerulean Pharma Business Overview
7.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.11.4 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.11.5 Cerulean Pharma Key News
7.12 Cipla
7.12.1 Cipla Corporate Summary
7.12.2 Cipla Business Overview
7.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.12.4 Cipla Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.12.5 Cipla Key News
7.13 Cornerstone Pharmaceuticals
7.13.1 Cornerstone Pharmaceuticals Corporate Summary
7.13.2 Cornerstone Pharmaceuticals Business Overview
7.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.13.4 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.13.5 Cornerstone Pharmaceuticals Key News
7.14 Curis
7.14.1 Curis Corporate Summary
7.14.2 Curis Business Overview
7.14.3 Curis Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.14.4 Curis Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.14.5 Curis Key News
7.15 CytRx
7.15.1 CytRx Corporate Summary
7.15.2 CytRx Business Overview
7.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.15.4 CytRx Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.15.5 CytRx Key News
7.16 Eli Lilly
7.16.1 Eli Lilly Corporate Summary
7.16.2 Eli Lilly Business Overview
7.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.16.4 Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.16.5 Eli Lilly Key News
7.17 Exelixis
7.17.1 Exelixis Corporate Summary
7.17.2 Exelixis Business Overview
7.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.17.4 Exelixis Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.17.5 Exelixis Key News
7.18 Fresenius Kabi
7.18.1 Fresenius Kabi Corporate Summary
7.18.2 Fresenius Kabi Business Overview
7.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.18.4 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.18.5 Fresenius Kabi Key News
7.19 Genentech
7.19.1 Genentech Corporate Summary
7.19.2 Genentech Business Overview
7.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.19.4 Genentech Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.19.5 Genentech Key News
7.20 Hikma Pharmaceuticals
7.20.1 Hikma Pharmaceuticals Corporate Summary
7.20.2 Hikma Pharmaceuticals Business Overview
7.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.20.4 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.20.5 Hikma Pharmaceuticals Key News
7.21 Hospira
7.21.1 Hospira Corporate Summary
7.21.2 Hospira Business Overview
7.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.21.4 Hospira Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.21.5 Hospira Key News
7.22 Intas Pharmaceuticals
7.22.1 Intas Pharmaceuticals Corporate Summary
7.22.2 Intas Pharmaceuticals Business Overview
7.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.22.4 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.22.5 Intas Pharmaceuticals Key News
7.23 Karyopharm Therapeutics
7.23.1 Karyopharm Therapeutics Corporate Summary
7.23.2 Karyopharm Therapeutics Business Overview
7.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.23.4 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.23.5 Karyopharm Therapeutics Key News
7.24 Kyowa Hakko Kirin
7.24.1 Kyowa Hakko Kirin Corporate Summary
7.24.2 Kyowa Hakko Kirin Business Overview
7.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.24.4 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.24.5 Kyowa Hakko Kirin Key News
7.25 Ligand Pharmaceuticals
7.25.1 Ligand Pharmaceuticals Corporate Summary
7.25.2 Ligand Pharmaceuticals Business Overview
7.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.25.4 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global (2016-2021)
7.25.5 Ligand Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com